IGLON5 and encephalitis: Among them, 35 (42.2%) patients were diagnosed with anti-NMDAR encephalitis, 24 (28.9%) with anti-LGl1 encephalitis, 13 (15.7%) with anti-GABABR encephalitis, eight with anti-CASPR2 encephalitis, two with anti-IgLON5, anti-DPPX and anti-mGluR5 encephalitis, and one with anti-AMPAR1 encephalitis.